Clinical trial
A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)
NCT00000836 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00000836 |
|---|---|
| Title | A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) |
| Official title | A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Retinitis, HIV Infections |
| Intervention type | Drug |
| Interventions | Sevirumab |
| Enrollment | 300 |
| Completion | Aug 1, 1998 |
| First posted | Aug 31, 2001 |
| Last update posted | Oct 25, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: